ercc6l Antibody

What is ERCC6L and what are its key cellular functions?

ERCC6L, also known as PICH (Plk1-interacting checkpoint helicase) or Tumor antigen BJ-HCC-15, is a 1250 amino acid protein containing helicase ATP-binding and C-terminal domains along with two TPR repeats. It functions as a DNA helicase that localizes to kinetochores and inner centromeres, belonging to the SNF2/RAD54 helicase family . Research has established its essential role in chromosome separation during cell mitosis . The protein has a calculated molecular weight of 46-141 kDa but is commonly observed at approximately 180 kDa in western blot analyses . ERCC6L is expressed in both the cytoplasm and nucleus of cells, with higher expression typically observed in the cytoplasm as demonstrated by immunohistochemistry studies .

Which applications are validated for ERCC6L antibody detection?

The ERCC6L antibody has been validated for multiple experimental applications with specific dilution recommendations:

Note: For IHC applications, antigen retrieval with TE buffer pH 9.0 is suggested; alternatively, citrate buffer pH 6.0 may be used . Sample-dependent optimization is recommended to obtain optimal results.

How should I prepare samples for ERCC6L detection in different cancer tissue types?

For optimal ERCC6L detection in cancer tissues, sample preparation protocols should be tailored to the specific tissue type. For paraffin-embedded sections, the standard procedure includes cutting sections, deparaffinization, rehydration, and heat treatment for antigen retrieval. After incubating sections with 3% hydrogen peroxide to inactivate endogenous peroxidase activity, treat with 5% normal blocking serum, followed by overnight incubation with the ERCC6L primary antibody .

For gastric cancer (GC) and colorectal cancer (CRC) tissues specifically, studies have successfully employed this protocol with subsequent treatment with biotinylated secondary antibody and SABC solution before visualization under light microscope . When evaluating ERCC6L expression by IHC, implement a scoring system that considers both staining intensity (0: negative; 1: weak; 2: medium; 3: strong) and immunostaining area (0: 0-5%; 1: 6-25%; 2: 26-50%) . A total score below 3 indicates negative expression, while 3 or above indicates positive expression.

How can I effectively use ERCC6L antibody to investigate its role in cancer progression?

To investigate ERCC6L's role in cancer progression, a multi-method approach combining protein detection and functional studies has proven effective. First, establish ERCC6L expression profiles in your cancer model using western blot analysis and IHC. Studies have demonstrated that ERCC6L is significantly upregulated in various cancer tissues compared to adjacent normal tissues, including colorectal cancer , gastric cancer , and breast cancer .

For functional studies, implement ERCC6L knockdown or overexpression systems using shRNA or overexpression constructs. For example, researchers successfully used commercial ERCC6L-specific shRNA and overexpression constructs with Lipofectamine 2000 transfection to manipulate ERCC6L levels in gastric cancer cell lines . Following expression modification, assess:

• Cell proliferation using CCK-8 assay (days 0-5)

• Colony formation ability (14-day culture followed by crystal violet staining)

• Cell cycle effects via flow cytometry

• Migration capacity through wound healing assays

• Invasion potential using transwell invasion assays

Multiple studies have demonstrated that ERCC6L knockdown significantly inhibits proliferation and colony-forming ability while affecting cell cycle progression, particularly arresting cells in G0/G1 phase .

What are the optimal experimental controls when validating ERCC6L antibody specificity?

When validating ERCC6L antibody specificity, implement a comprehensive set of controls:

• Positive and negative tissue controls: Use tissues known to express ERCC6L (such as cancer cell lines HT29, SW480, HCT116 for high expression) and those with minimal expression (such as normal colonic mucosal NCM460 cells) .

• Genetic controls: Implement ERCC6L knockdown or knockout models. Studies have utilized siRNA approaches in colorectal cancer and shRNA in gastric cancer to reduce ERCC6L expression, which serves as an excellent negative control for antibody specificity testing.

• Conditional knockout models: For in vivo validation, consider using conditional knockout mouse models as demonstrated in breast cancer studies . This provides the gold standard for antibody specificity verification.

• Multiple detection methods: Cross-validate expression using different techniques: RT-qPCR for mRNA level and western blot plus IHC for protein level detection, as demonstrated in studies on colorectal cancer tissues .

How do ERCC6L expression patterns differ across cancer types, and what are the implications for experimental design?

ERCC6L expression varies significantly across cancer types, which has important implications for experimental design:

• Colorectal cancer: ERCC6L is highly expressed in CRC tissues compared to adjacent non-cancerous tissues. Expression correlates significantly with tumor size (p<0.05) but not with other clinical features like age, gender, differentiation, or clinical stage . For CRC research, focus experimental design on proliferation and invasion assays.

• Gastric cancer: ERCC6L is upregulated in GC tissues and associated with tumor size, clinical stage, and poor prognosis . In experimental design for GC, prioritize measuring both proliferation and metastatic potential, particularly assessing epithelial-mesenchymal transition (EMT) markers, as ERCC6L overexpression increases p-NF-κB p65 and N-cadherin expression while decreasing E-cadherin expression .

• Breast cancer: ERCC6L is highly expressed in breast cancer, especially in triple-negative breast cancer (TNBC), and correlates with poor patient outcomes . When designing breast cancer experiments, include mammary gland development studies and focus on tumorigenesis mechanisms.

This differential expression pattern necessitates cancer-specific optimization of antibody dilutions and detection methods. Additionally, when designing functional studies, researchers should prioritize the most relevant phenotypic assays based on ERCC6L's primary roles in each cancer type.

What are common issues when using ERCC6L antibody in Western blot applications and how can they be resolved?

When using ERCC6L antibody for Western blot applications, researchers may encounter several challenges:

Challenge 1: Variable molecular weight detection
The calculated molecular weight of ERCC6L ranges from 46-141 kDa, but it is commonly observed at approximately 180 kDa in Western blot analyses . This discrepancy can cause confusion in band identification.

Solution: Include positive controls (e.g., HeLa cells or Jurkat cells) known to express ERCC6L and verify using ERCC6L knockdown samples. Use protein ladder markers that span a wide range of molecular weights to accurately identify the target band.

Challenge 2: Low signal strength
Solution: Optimize antibody concentration within the recommended range (1:1000-1:6000) . Increase protein loading while ensuring equal loading across wells. Consider using enhanced chemiluminescence detection systems with extended exposure times. Fresh preparation of antibody dilutions can also improve signal strength.

Challenge 3: High background
Solution: Increase blocking time with 5% BSA or non-fat dry milk. Optimize washing steps (3-5 washes, 5-10 minutes each) with TBST or PBST. Reduce primary antibody concentration and ensure proper membrane blocking before antibody incubation.

How can I optimize ERCC6L antibody for immunohistochemistry in different tissue types?

Optimizing ERCC6L antibody for IHC requires careful attention to tissue-specific parameters:

• Antigen retrieval optimization: For ERCC6L antibody, TE buffer at pH 9.0 is generally recommended, though citrate buffer at pH 6.0 may be used alternatively . Test both methods to determine optimal retrieval conditions for your specific tissue type.

• Antibody dilution titration: Begin with a dilution series within the recommended range (1:50-1:500) . For each tissue type (e.g., colon, gastric, breast), create a dilution gradient to identify the optimal concentration that maximizes specific staining while minimizing background.

• Incubation conditions: Test various primary antibody incubation times (overnight at 4°C versus 1-2 hours at room temperature) and temperatures to determine optimal conditions for your tissue.

• Detection system selection: Compare various detection systems (ABC, polymer-based) to identify which provides optimal signal-to-noise ratio for ERCC6L in your tissue of interest.

• Blocking optimization: For tissues with high background, increase blocking serum concentration from 5% to 10% and extend blocking time to 1-2 hours .

The scoring system for ERCC6L expression should consider both staining intensity and area as described previously , with careful evaluation of subcellular localization patterns since ERCC6L is expressed in both cytoplasm and nucleus with typically higher cytoplasmic expression .

How should I interpret conflicting ERCC6L expression data between different detection methods?

When facing discrepancies between different detection methods for ERCC6L expression:

• Validate at multiple levels: Confirm expression at both mRNA level (via RT-qPCR) and protein level (via Western blot and IHC) as demonstrated in studies of colorectal cancer tissues . RNA-seq data can provide additional validation.

• Consider tissue heterogeneity: ERCC6L expression can vary within a tumor sample. While Western blot provides an average expression across the entire tissue sample, IHC reveals spatial distribution patterns. Studies have shown that ERCC6L is expressed in both cytoplasm and nucleus, with typically higher cytoplasmic expression . This heterogeneity may explain apparent discrepancies between methods.

• Evaluate antibody specificity: Verify antibody specificity by comparing results from multiple ERCC6L antibody clones or sources. Include ERCC6L knockdown controls to confirm signal specificity .

• Normalize appropriately: For accurate quantitative comparisons, ensure proper normalization for each method: housekeeping genes for RT-qPCR, loading controls for Western blot, and appropriate negative controls for IHC.

• Consider post-translational modifications: Discrepancies may arise from post-translational modifications affecting antibody recognition. In such cases, use antibodies recognizing different epitopes of ERCC6L.

What cell-based assays are most effective for studying ERCC6L function in cancer models?

Based on published research, the following cell-based assays have proven most effective for studying ERCC6L function in cancer:

• Proliferation assays: The CCK-8 assay performed over multiple days (0-5) effectively demonstrates the impact of ERCC6L on cell growth rates . EdU incorporation assays provide complementary data on DNA synthesis activity .

• Colony formation assay: 14-day culture followed by crystal violet staining and colony counting (>50 cells/colony) reveals long-term growth effects of ERCC6L manipulation .

• Cell cycle analysis: Flow cytometry following ERCC6L knockdown has demonstrated cell cycle arrest at G0/G1 phase in colorectal cancer cells . This assay is crucial for understanding ERCC6L's role in cell cycle progression.

• Migration assays: Wound healing assays with measurements at 0 and 48 hours effectively quantify the impact of ERCC6L on cell migration . Calculate wound closure rate as: (0h width–48h width)/0h width × 100%.

• Invasion assays: Transwell invasion assays have shown that ERCC6L knockdown significantly decreases cancer cell invasion capacity .

• EMT marker analysis: Western blot analysis of EMT markers (E-cadherin, N-cadherin) following ERCC6L manipulation reveals mechanisms of metastasis promotion, particularly in gastric cancer models .

When designing these experiments, include appropriate controls of ERCC6L knockdown and overexpression models, and consider differences between cancer cell lines. For example, the SW480 colorectal cancer cell line showed higher ability to migrate, invade and clone compared to HT29 cells, with significant cell cycle arrest at G0/G1 observed only in HT29 cells .

How can I investigate the relationship between ERCC6L and clinical outcomes in cancer patients?

To investigate the relationship between ERCC6L and clinical outcomes in cancer patients:

What molecular mechanisms link ERCC6L to cancer progression, and how can they be studied?

Several molecular mechanisms connecting ERCC6L to cancer progression have been identified:

• Cell cycle regulation: ERCC6L knockdown induces G0/G1 phase arrest in colorectal cancer cells . To investigate this mechanism:

  • Perform cell cycle analysis using flow cytometry

  • Analyze expression of cell cycle regulators (cyclins, CDKs) by Western blot after ERCC6L manipulation

  • Use CDK inhibitors to determine whether they phenocopy ERCC6L knockdown effects

• EMT promotion: In gastric cancer, ERCC6L overexpression increases p-NF-κB p65 and N-cadherin while decreasing E-cadherin . To study this pathway:

  • Analyze EMT markers (E-cadherin, N-cadherin, vimentin) following ERCC6L manipulation

  • Investigate transcription factors driving EMT (Snail, Slug, ZEB1/2) through qRT-PCR and Western blot

  • Assess NF-κB pathway activation using phosphorylation-specific antibodies and reporter assays

  • Employ NF-κB inhibitors to determine if they can reverse ERCC6L-induced phenotypes

• Chromosome separation: As an essential protein in chromosome separation during mitosis , ERCC6L may promote genomic instability in cancer. To explore this:

  • Assess micronuclei formation following ERCC6L depletion

  • Analyze chromosomal abnormalities using karyotyping or fluorescence in situ hybridization

  • Investigate DNA damage markers (γ-H2AX) and the DNA damage response pathway

• Signaling pathway interactions: Investigate potential connections between ERCC6L and established cancer pathways:

  • Examine interactions with KRAS and BRAF mutations, which may explain differential effects observed between cancer cell lines

  • Screen for kinases that phosphorylate ERCC6L using phospho-proteomic approaches

  • Perform co-immunoprecipitation assays to identify ERCC6L binding partners

These mechanisms can be studied using integrated approaches combining genetic manipulation (shRNA knockdown, CRISPR/Cas9 knockout, or overexpression) with functional assays and biochemical techniques to elucidate the complex roles of ERCC6L in cancer progression.

What are emerging applications of ERCC6L antibody in cancer diagnosis and treatment?

ERCC6L antibody shows promise in several emerging applications for cancer research:

• Biomarker development: Given ERCC6L's differential expression in various cancers and association with clinical outcomes, it holds potential as a diagnostic and prognostic biomarker. Future research should focus on standardizing detection methods and establishing clinically relevant expression thresholds for different cancer types.

• Therapeutic target validation: Research indicates ERCC6L promotes cancer cell growth and invasion across multiple cancer types . Further investigation using ERCC6L antibodies in combination with inhibitor screening could validate ERCC6L as a therapeutic target. The finding that "ERCC6L may be a potential new target for cancer therapy" suggests avenues for developing targeted treatments.

• Combination therapy research: ERCC6L's role in cell cycle regulation suggests potential synergies with existing chemotherapeutics. Antibody-based detection of ERCC6L could identify tumors likely to respond to such combination approaches.

• Early detection strategies: Given its upregulation in early-stage cancers, ERCC6L antibody-based detection systems might enable earlier diagnosis, particularly in high-risk populations for colorectal, gastric, and breast cancers.

• Liquid biopsy development: Exploring ERCC6L detection in circulating tumor cells or cell-free DNA could provide minimally invasive diagnostic and monitoring tools.

Future research should focus on optimizing antibody specificity and sensitivity for these applications, potentially through development of monoclonal antibodies targeting cancer-specific epitopes or post-translational modifications of ERCC6L.